stockrow
Friday 6 November 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
- EPS
- +38.6%
- Free cash flow
- +34.8%
Quarter to June 2026, against a year earlier
0.99
0.05
−4.81%
Follow SKYE
Alert me
Skye Bioscience, Inc. (SKYE) P/E ratio
Skye Bioscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 18.0× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 18.0×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ADTX Aditxt, Inc. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. | n/m |
| IMNN Imunon, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| AZTR Azitra, Inc. compare | 1.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)